(Q37823559)

23 August 2017

1 reference

title

The impact of disease stage on direct medical costs of HIV management: a review of the international literature (English)

1 reference

23 August 2017

0 references

5

Julio Montaner

1 reference

23 August 2017

2

Karissa Johnston

1 reference

23 August 2017

Adrian Levy

1

1 reference

23 August 2017

Lieven Annemans

series ordinal

3

1 reference

23 August 2017

Andrea Tramarin

series ordinal

4

1 reference

23 August 2017

publication date

1 January 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

28 Suppl 1

1 reference

23 August 2017

page(s)

35-47

1 reference

https://scigraph.springernature.com/pub.10.2165/11587430-000000000-00000

23 August 2017

exact match

0 references

cites work

The AIDS epidemic--considerations for the 21st century

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Twenty years of therapy for HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

The survival benefits of AIDS treatment in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

The changing face of the HIV epidemic in western Europe: what are the implications for public health policies?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Rates and Risk Factors for Condition-Specific Hospitalizations in HIV-Infected and Uninfected Women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

The direct costs of HIV/AIDS care

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

The cost of care for patients with HIV from the provider economic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Distribution of health care expenditures for HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Hospital and outpatient health services utilization among HIV-infected patients in care in 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

The treatment and care costs of people with HIV infection or AIDS: development of a standardised cost framework for Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Economic Notes: opportunity cost

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

The cost of HIV treatment and care. A global review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Indirect cost of HIV infection in England.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

The cost effectiveness of combination antiretroviral therapy for HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

The case for conservative management of early HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

The case for earlier treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

Treat HIV-1 infection like other infections--treat it.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies

21 January 2018

2 references

https://api.crossref.org/works/10.2165%2F11587430-000000000-00000

21 January 2018

12 December 2020

Costs of HIV medical care in the era of highly active antiretroviral therapy

1 reference

12 December 2020

Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.

1 reference

12 December 2020

Prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome in resource-limited settings

1 reference

12 December 2020

Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA

1 reference

12 December 2020

Indirect costs of HIV/AIDS mortality in Canada

1 reference

12 December 2020

The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection

1 reference

12 December 2020

The economic value of human life

1 reference

12 December 2020

10.2165/11587430-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1033300829

0 references

1 reference